-
Evaluating Protease Inhibitor Libraries for Drug Discovery W
2026-05-09
Kralj et al. critically review commercial molecular libraries designed for SARS-CoV-2 and protease inhibition, highlighting both their design methodologies and notable shortcomings in transparency and functional annotation. The paper underscores the need for robust, well-characterized compound libraries to advance virtual screening and computer-aided drug design.
-
Efficient Annexin V Purification: Enabling Biophysical Studi
2026-05-08
This study introduces a rapid and efficient method for purifying recombinant annexin V, essential for advanced biophysical analyses of ion channel activity. The protocol minimizes contaminants and preserves protein integrity, supporting high-resolution structural and electrophysiological investigations.
-
N1-Methyl-Pseudouridine-5'-Triphosphate in mRNA Synthesis
2026-05-07
N1-Methyl-Pseudouridine-5'-Triphosphate (N1-Methylpseudo-UTP) enables next-generation mRNA synthesis by enhancing RNA stability and translational fidelity, supporting robust applications in vaccine development and RNA-based assays. By integrating this modified nucleotide into in vitro transcription workflows, researchers can overcome common pitfalls in RNA degradation and boost the effectiveness of experimental and therapeutic mRNA.
-
Pharmacokinetics of Corydalis saxicola Alkaloids in MASH Mod
2026-05-07
This study systematically characterizes the pharmacokinetic variability and tissue distribution of Corydalis saxicola Bunting total alkaloids in mice with metabolic dysfunction-associated steatohepatitis (MASH). The findings highlight disease-induced modulation of metabolism and transporter expression, informing future rational dosing strategies for MASLD/MASH interventions.
-
miR-122-5p Modulates PKM2 to Drive Insulin Resistance in Met
2026-05-06
Zhou et al. (2025) uncover the regulatory relationship between miR-122-5p and PKM2 in the context of metabolic syndrome, demonstrating that miR-122-5p promotes insulin resistance and abnormal glucose metabolism by downregulating PKM2. These mechanistic insights highlight miR-122-5p as a predictive biomarker and potential therapeutic target for metabolic syndrome.
-
GOT1 Inhibition by Ziprasidone Reprograms PDAC Metabolism
2026-05-06
The referenced study identifies ziprasidone as a novel non-competitive inhibitor of GOT1, disrupting glutamine metabolism and redox balance in pancreatic ductal adenocarcinoma (PDAC) cells. These findings highlight GOT1 as a promising metabolic target in PDAC, with mechanistic implications for redox regulation and tumor growth control.
-
DiscoveryProbe Protease Inhibitor Library: Assay Precision a
2026-05-05
Explore how the DiscoveryProbe Protease Inhibitor Library transforms protease inhibition research by enabling precise, resistance-aware screening. Gain advanced insights into assay design and selectivity, setting this resource apart in drug discovery.
-
Advancing Osteoclastogenesis Assays with (S)-1-(3-fluoro-4..
2026-05-05
(S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea (BPN-19186) enables robust, reproducible modulation of the Nrf2 pathway in osteoclastogenesis, with proven workflow compatibility and high solubility. This guide translates the latest mechanistic research and hands-on troubleshooting strategies into actionable protocols for bone biology and beyond.
-
Oligo (dT) 25 Beads: Precision Eukaryotic mRNA Isolation
2026-05-04
Oligo (dT) 25 Beads enable high-purity eukaryotic mRNA isolation through superparamagnetic bead technology. Their specificity for polyA tails and compatibility with molecular biology workflows make them a benchmark for next-generation sequencing and RT-PCR applications.
-
Rapamycin (Sirolimus): Applied mTOR Inhibition in Cell Model
2026-05-04
Leverage Rapamycin (Sirolimus) for precise mTOR pathway modulation in cancer, immunology, and mitochondrial disease models. This article provides actionable workflows, troubleshooting strategies, and practical insights to maximize reproducibility and data integrity in advanced cellular assays.
-
YM-155 Hydrochloride: Redefining Survivin Inhibition in Comp
2026-05-03
Explore how YM-155 hydrochloride, a potent survivin inhibitor, enables more nuanced drug response evaluation and advances apoptosis inhibitor research. This article uniquely integrates in-depth product properties with cutting-edge assay strategy for translational cancer studies.
-
Optimizing hiPSC Platelet Production via Small Molecule Modu
2026-05-02
This study details a systematically optimized protocol for generating functional platelets from human induced pluripotent stem cells (hiPSCs), integrating small molecule modulators to enhance yield, reduce cost, and improve megakaryocyte maturation. The approach provides a scalable and cost-effective strategy for platelet manufacturing, with important implications for cell therapy and regenerative medicine.
-
Protoporphyrin IX in Ferroptosis Modulation and Cancer Thera
2026-05-02
Explore the multifaceted roles of Protoporphyrin IX as a photodynamic compound in heme formation, ferroptosis modulation, and advanced cancer therapy. This article offers a distinct, assay-focused perspective informed by recent mechanistic discoveries.
-
Ceftolozane-Tazobactam in Nosocomial Pneumonia: Comparative
2026-05-01
This article examines the molecular and clinical innovations of ceftolozane-tazobactam for treating nosocomial pneumonia, focusing on its activity against multidrug-resistant Pseudomonas aeruginosa and Enterobacteriaceae. The findings clarify how specific structural modifications enhance spectrum and resistance stability, informing antibiotic selection and future research into Gram-negative infection models.
-
Evaluating Commercial Protease Inhibitor Libraries for Virtu
2026-04-30
Kralj et al. critically analyze the design and transparency of commercial molecular libraries, especially those focused on protease inhibition and SARS-CoV-2 targets. Their review highlights considerable gaps in methodological reporting, which impacts the utility of these libraries for structure-based and ligand-based virtual screening in drug discovery.